Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO 300 Oral Suspension in healthy volunteers
NCT06741345Phase 1Completed
- Sponsor
- Humanetics
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BIO 300 (3 arms), sponsored by Humanetics. Primary endpoint: Adverse Events. Started Dec 2024; status: completed.
02
Drugs
BIO 300
Beyond the preview
Go deeper on NCT06741345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741345.